If you're wanting to build a strong portfolio, then having a few blue chips in there could be a good starting point.
Blue chips are typically large companies that have been operating for many years, have stable cash flows, and experienced management teams. This can make them lower risk options and a good foundation to build a portfolio from.
But which blue chip ASX 200 shares could be in the buy zone? Here are three to consider:
Image source: Getty Images
CSL Limited (ASX: CSL)
The first blue chip ASX 200 share to consider is CSL. It is one of the world's leading biotechnology companies, comprising the CSL Behring business and the Seqirus business. It appears well-placed for growth over the long term thanks to strong demand for its immunoglobulins and its lucrative research and development pipeline. Macquarie is a fan of the company and has an outperform rating and $338.00 price target
Goodman Group (ASX: GMG)
Another blue chip ASX 200 share to look at is Goodman Group. It is a leading integrated commercial and industrial property company that has been growing at a solid rate over the last decade. This has been driven by the overwhelming success of its strategy of developing high quality industrial properties in strategic locations, close to large urban populations and in and around major gateway cities globally. The team at Citi appear confident this strategy will underpin further strong growth in the years to come. Its analysts have a buy rating and $27.50 price target on its shares.
ResMed Inc. (ASX: RMD)
A final blue chip ASX 200 share to look at is ResMed. It is a sleep treatment-focused medical device company with a portfolio of industry-leading products improving the lives of sufferers of conditions such as sleep apnoea. The good news is that this is a huge market with just an estimated one fifth of sufferers currently diagnosed. This gives ResMed a long runway for growth in the future. Credit Suisse is positive on ResMed. It has an outperform rating and $43.00 price target on the company's shares.
